[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE513827T1 - Oxyindol-derivate als 5ht4-rezeptor-agonisten - Google Patents

Oxyindol-derivate als 5ht4-rezeptor-agonisten

Info

Publication number
ATE513827T1
ATE513827T1 AT06710525T AT06710525T ATE513827T1 AT E513827 T1 ATE513827 T1 AT E513827T1 AT 06710525 T AT06710525 T AT 06710525T AT 06710525 T AT06710525 T AT 06710525T AT E513827 T1 ATE513827 T1 AT E513827T1
Authority
AT
Austria
Prior art keywords
receptor agonists
oxyindole derivatives
oxyindole
derivatives
agonists
Prior art date
Application number
AT06710525T
Other languages
English (en)
Inventor
Kiyoshi Kawamura
Hiroki Sone
Chikara Uchida
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE513827T1 publication Critical patent/ATE513827T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT06710525T 2005-02-22 2006-02-10 Oxyindol-derivate als 5ht4-rezeptor-agonisten ATE513827T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65527605P 2005-02-22 2005-02-22
PCT/IB2006/000519 WO2006090279A1 (en) 2005-02-22 2006-02-10 Oxyindole derivatives as 5ht4 receptor agonists

Publications (1)

Publication Number Publication Date
ATE513827T1 true ATE513827T1 (de) 2011-07-15

Family

ID=36579484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06710525T ATE513827T1 (de) 2005-02-22 2006-02-10 Oxyindol-derivate als 5ht4-rezeptor-agonisten

Country Status (32)

Country Link
US (2) US7589109B2 (de)
EP (1) EP1856110B1 (de)
JP (1) JP4130220B1 (de)
KR (1) KR100908547B1 (de)
CN (1) CN101522668B (de)
AP (1) AP2007004067A0 (de)
AR (1) AR053548A1 (de)
AT (1) ATE513827T1 (de)
AU (1) AU2006217534B8 (de)
BR (1) BRPI0607456A2 (de)
CA (1) CA2598536C (de)
DK (1) DK1856110T3 (de)
DO (1) DOP2006000046A (de)
EA (1) EA012615B1 (de)
ES (1) ES2366375T3 (de)
GE (1) GEP20094727B (de)
GT (1) GT200600083A (de)
HK (1) HK1135966A1 (de)
HN (1) HN2006007884A (de)
IL (1) IL184505A0 (de)
MA (1) MA29260B1 (de)
MX (1) MX2007010139A (de)
NL (1) NL1031218C2 (de)
NO (1) NO20073566L (de)
NZ (1) NZ556627A (de)
PE (1) PE20061096A1 (de)
TN (1) TNSN07319A1 (de)
TW (1) TW200640915A (de)
UA (1) UA86301C2 (de)
UY (1) UY29389A1 (de)
WO (1) WO2006090279A1 (de)
ZA (1) ZA200706420B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
AP2007004067A0 (en) * 2005-02-22 2007-08-31 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
CN101212974A (zh) * 2005-06-29 2008-07-02 默克公司 4-氟-哌啶t-型钙通道拮抗剂
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP5205971B2 (ja) * 2006-01-27 2013-06-05 宇部興産株式会社 テトラヒドロピラン化合物の製造方法
WO2008021422A2 (en) * 2006-08-17 2008-02-21 Wyeth Process for the preparation of indolin-2-one derivatives useful as pr modulators
KR101697773B1 (ko) * 2008-03-10 2017-01-18 유로드러그 레버러토리즈 비. 브이. 독소필린을 포함하는 변형 방출 조성물
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
JP5663743B2 (ja) * 2009-02-27 2015-02-04 ラクオリア創薬株式会社 モチリン受容体作動活性を有するオキシインドール誘導体
WO2010129757A1 (en) * 2009-05-07 2010-11-11 United Therapeutics Corporation Solid formulations of prostacyclin analogs
CA2771885C (en) 2009-09-14 2014-04-08 Suven Life Sciences Limited 1,2-dihydro-2-oxoquinoline compounds as 5-ht4receptor ligands
MX343165B (es) * 2010-02-12 2016-10-26 Raqualia Pharma Inc Agonistas del receptor 5-ht4 para el tratamiento de demencia.
SG2014003560A (en) * 2011-09-19 2014-11-27 Suven Life Sciences Ltd Heteroaryl compounds as 5-ht4 receptor ligands
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
BR112016018555B1 (pt) 2014-02-13 2024-01-23 Incyte Holdings Corporation Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
EP3105218B1 (de) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamine als lsd1-hemmer
EP3392244A1 (de) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamine als lsd1-inhibitoren
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
KR102659373B1 (ko) 2015-04-03 2024-04-23 인사이트 홀딩스 코포레이션 Lsd1 저해제로서 헤테로사이클릭 화합물
US10329255B2 (en) * 2015-08-12 2019-06-25 Incyte Corporation Salts of an LSD1 inhibitor
ES2906791T3 (es) * 2016-02-16 2022-04-20 Strongbridge Dublin Ltd Composiciones farmacéuticas de veldoreotida soluble en agua con escasa solubilidad en condiciones fisiológicas y métodos de producción
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN114105863B (zh) * 2021-12-07 2023-11-28 江苏汉拓光学材料有限公司 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
US5552408A (en) * 1987-09-23 1996-09-03 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
JPH06506443A (ja) 1991-01-09 1994-07-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9121170D0 (en) 1991-10-05 1991-11-20 Smithkline Beecham Plc Pharmaceuticals
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5280028A (en) * 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5300512A (en) * 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
US5521193A (en) * 1992-06-24 1996-05-28 G. D. Searle & Co. Benzimidazole compounds
FR2694292B1 (fr) 1992-07-29 1994-10-21 Esteve Labor Dr Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament.
JPH08502741A (ja) * 1992-11-05 1996-03-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ▲下４▼レセプターアンタゴニスト用のピペリジン誘導体
TW251287B (de) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9312348D0 (en) 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
US5534521A (en) * 1993-06-23 1996-07-09 G. D. Searle & Co. Benzimidazole compounds
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
GB9414139D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
DE4440675A1 (de) 1994-11-14 1996-05-15 Basf Ag Verfahren zur Herstellung von kautschukmodifizierten Formmassen mittels in den Kautschuk eingebauten, bei thermischer Zersetzung Radikale bildenden Gruppen
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
AU9309898A (en) * 1997-09-09 1999-03-29 Du Pont Pharmaceuticals Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6310059B1 (en) * 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
WO2000026197A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
JP2003518107A (ja) 1999-12-20 2003-06-03 ニューロメド テクノロジーズ， インコーポレイテッド 部分飽和カルシウムチャネルブロッカー
AU2002216314A1 (en) 2000-10-12 2002-04-22 Scott A Henderson Heterocyclic angiogenesis inhibitors
EP1341773A2 (de) * 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituierte 1,3,5-triazine und pyrimidine als abca-1-expressions-stimulierende verbindungen gegen koronararterien-erkrankungen oder atherosclerose
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
WO2004113300A1 (ja) 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
OA13248A (en) * 2003-09-03 2007-01-31 Pfizer Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity.
GEP20094638B (en) * 2004-06-15 2009-03-10 Pfizer Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
AP2007004067A0 (en) * 2005-02-22 2007-08-31 Pfizer Oxyindole derivatives as 5HT4 receptor agonists

Also Published As

Publication number Publication date
JP2008531543A (ja) 2008-08-14
EP1856110B1 (de) 2011-06-22
ZA200706420B (en) 2009-04-29
AR053548A1 (es) 2007-05-09
AU2006217534B8 (en) 2011-12-08
HK1135966A1 (en) 2010-06-18
GT200600083A (es) 2006-11-07
TW200640915A (en) 2006-12-01
MA29260B1 (fr) 2008-02-01
AU2006217534B2 (en) 2011-08-11
CA2598536C (en) 2011-04-05
IL184505A0 (en) 2007-10-31
UY29389A1 (es) 2006-10-02
US20100173925A1 (en) 2010-07-08
MX2007010139A (es) 2007-09-27
NZ556627A (en) 2010-09-30
US7589109B2 (en) 2009-09-15
AU2006217534A8 (en) 2011-12-08
EP1856110A1 (de) 2007-11-21
TNSN07319A1 (fr) 2008-12-31
EA012615B1 (ru) 2009-10-30
HN2006007884A (es) 2010-01-18
JP4130220B1 (ja) 2008-08-06
UA86301C2 (en) 2009-04-10
EA200701552A1 (ru) 2007-12-28
DOP2006000046A (es) 2006-08-31
BRPI0607456A2 (pt) 2009-09-08
NL1031218C2 (nl) 2007-01-23
KR100908547B1 (ko) 2009-07-20
AU2006217534A1 (en) 2006-08-31
AP2007004067A0 (en) 2007-08-31
NO20073566L (no) 2007-08-08
NL1031218A1 (nl) 2006-08-23
KR20070098936A (ko) 2007-10-05
CN101522668B (zh) 2012-06-06
CA2598536A1 (en) 2006-08-31
WO2006090279A1 (en) 2006-08-31
DK1856110T3 (da) 2011-08-15
ES2366375T3 (es) 2011-10-19
US20060194842A1 (en) 2006-08-31
GEP20094727B (en) 2009-07-10
CN101522668A (zh) 2009-09-02
PE20061096A1 (es) 2006-11-09

Similar Documents

Publication Publication Date Title
ATE513827T1 (de) Oxyindol-derivate als 5ht4-rezeptor-agonisten
ATE509927T1 (de) Indolderivate als s1p1-rezeptor-agonisten
DE602006003628D1 (de) Purinderivate als a2a-rezeptoragonisten
ATE504559T1 (de) Arylanilinderivate als agonisten des beta2- adrenergen rezeptors
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
DK1863474T3 (da) Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
ATE480524T1 (de) Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
DE602005026867D1 (de) Entzündungshemmende indol-derivate
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
DE602006019624D1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE539056T1 (de) Piperidinderivate als agonisten muskariner rezeptoren
DE602006004768D1 (de) Carboxamid derivate als muskarin rezeptor antagonisten
ATE535523T1 (de) Benzimidazolcarbonsäureamid-verbindungen als 5- ht4 rezeptor-agonisten
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
DE602006003666D1 (de) Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
DE602004009796D1 (de) Imidazolderivate als glutamatrezeptorantagonisten
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
DE602006008002D1 (de) Benzofuranylderivate als 5-ht6-rezeptorinhibitoren
ATE435225T1 (de) Oxadiazolonderivate als ppar-delta-agonisten
ATE472544T1 (de) Als via-rezeptor-antagonisten verwendbare indole
ATE488519T1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties